Benjamin Cameransi, MD
Co-Founder & Managing Partner
Ben is an accomplished physician executive specializing in drug delivery and pharmaceutical IP. He leads a skilled team focused on advancing the use of acidic cannabinoids in healthcare. With a history of success as a Co-Founder of Lyotropic Therapeutics, he secured funding and FDA approval for Ryanodex™, which received Orphan Drug Designation for Malignant Hyperthermia. This product was licensed to and is marketed by Eagle Pharmaceuticals. Dr. Cameransi also co-founded a biotech company that was acquired by Theracel Corporation, and they licensed Vitamin C-analog products to Forest Laboratories. He has served on Scientific Advisory Boards for several startups, guiding them to NASDAQ IPOs. His clinical expertise as a Board-Certified Anesthesiologist has driven innovation in anesthesia services and pain management practices to enhance patient care and outcomes.
Mark Hines, MD
Vice President, Product Development
Mark is co-principal of Mingowood Pharmacal and Vice President of Product Development. He is a triple board-certified interventional pain physician and former state president of the North Carolina American Society of Interventional Pain Physicians. Dr. Hines has over 25 years of experience in the medical industry with a particular focus in biopharmaceuticals, developing early stage, novel technologies tailored towards drug and nutraceutical development across multiple therapeutic areas, especially those that treat pain and metabolic comorbidities. He also serves as the CEO of Intersect Partners, LLC, specializing in complementary Med-Tech solutions as well as the CEO of Venturix, LLC, a venture capital firm for accredited and non-accredited investors seeking capital growth through new medical technologies and pharmaceuticals. He has a deep interest in finding new and innovative medical discoveries destined to make large impacts in healthcare and source funding for several startups in the biotechnology space.
Dave Anderson, PhD.
Chief Scientific Officer
Dave's academic journey commenced at the University of Minnesota, where he conducted groundbreaking research, yielding mathematical insights into complex microstructures, including Lipid NanoParticles (LNPs) utilized in drug delivery. His transition into the realm of patents led to significant innovations, particularly in the development of controlled-pore materials, airborne virus detection, and lipid nanoparticles for targeted drug delivery. These patents have not only advanced pharmaceutical products but have also been instrumental in the realm of RNA delivery, as evident in applications such as Covid vaccines and gene therapy. Dr. Anderson's versatile career spans academia, defense, and industry, where his profound mathematical knowledge has empowered him to conduct sophisticated material analyses and drive innovative product development. His remarkable track record includes an impressive patent allowance rate, emphasizing his acute ability to identify patentable inventions. His contributions extend to science-based product innovations, such as drug delivery through clothing and the development of FDA-approved injectable products, further cementing his impact on the field.
Kay Braymer Peterson
Vice President, Business Development
Kay is an adaptable and dynamic leader with over 30 years’ experience driving change and transformation across organizations. She understands how to develop and implement innovative business strategies that enable organizations to move forward and achieve sustainable goals in competitive market conditions. Kay has been responsible for the launch of new business processes, creation of marketplace strategies, as well as leading sales and business operations.
Prior to joining Mingowood, Kay held sales and marketing roles at KPMG, QAD, Oracle/Peoplesoft/JD Ewards and IBM.